Medical Device Media Reporting Pioneer
Share Professional Medical Device Knowledge
Source:Instrument Family,Reprint is prohibited without authorization, and reprinting is allowed 24 hours later.
May 15,GE Healthcare Announces Signing of Investment Cooperation Intent Agreement with Shanghai Pudong New Area Science and Technology and Economy Committee, Increasing Investment by 380 Million RMB, for cooperation intentions in multiple areas such as new product introduction and new production line construction, factory green upgrades, intelligent manufacturing, and digital transformation.It is worth mentioning that this year also marks the 30th anniversary of the establishment of GE Healthcare's Shanghai production base for diagnostic drugs (hereinafter referred to as the "Shanghai Base") in Zhangjiang, Pudong. GE Healthcare moved in shortly after the establishment of the Zhangjiang Biomedical Base in 1994.
GE Healthcare Invests an Additional 380 Million Yuan in Pudong
After more than 30 years of development, Pudong New Area has gathered over 3,900 biopharmaceutical enterprises, including 750 foreign-invested companies, becoming one of the regions in China with the most complete biopharmaceutical industry chain, the best ecosystem, the most concentrated talent pool, and the most active innovation. Zhangjiang Pharma Valley has also become an internationally renowned industrial calling card.Represented by GE Healthcare, a group of biopharmaceutical enterprises have also achieved synchronized development and concerted efforts with the biopharmaceutical industry in Pudong.
Since GE Healthcare's establishment in 1994, it has embarked on a journey of manufacturing diagnostic drugs in China and serving the world. Today,GE Healthcare's Shanghai base has achieved full localization of contrast agents for CT and MRI enhancement scans in China.To become one of the most important global medical contrast agent production bases for GE Healthcare,Ranked first in the list of Chinese export medical enterprises for many consecutive years, supplying the global market.Every second, four patients worldwide use GE Healthcare's diagnostic drugs for examination.It is reported that, based on the investment cooperation intention, GE Healthcare will work with Pudong New Area to implement more new diagnostic drug products and production lines.Green upgrade and transformation of factories, increasing the intensity of smart manufacturing and digital transformation, thereby further enhancing China's production capabilities and capacity.Promote more innovative achievements in diagnostic drugs through cooperation and transformation.For example,GE Healthcare's medical contrast agents are widely used in clinical pathways such as X-ray, CT, MRI, and ultrasound contrast imaging.As the "scout" of imaging examinations, medical contrast agents can greatly enhance the accuracy of tests and support the formulation of better clinical solutions. Further expanding the product line at the Shanghai site and increasing its importance in GE Healthcare's global supply chain will not only empower precise clinical diagnosis and decision-making but also drive upgrades across the upstream and downstream segments of the industry and innovation chains. This will allow high-quality innovative drugs to benefit clinical practice more quickly and promote the large-scale implementation of precision medicine in China.For example, through the intelligent green factory upgrade project, in the next three years,The Shanghai facility is expected to achieve a carbon emission reduction of nearly 840 tons, save 4,300 tons of steam, and conserve 196,000 kilowatt-hours of electricity.At the same time,The Shanghai site will officially be designated as the "GE Healthcare Diagnostic Pharmaceuticals Belt and Road Excellence Manufacturing Center."This Center of Excellence will fully leverageThe core hub value of diagnostic drug supply serving the globe,To allow more innovative achievements made in China to benefit patients and doctors around the world, strengthen resource sharing and cooperation, promote the upgrading and high-quality development of the diagnostic pharmaceuticals industry chain, and help Shanghai Pudong build a world-class biomedicine industry cluster.Promote the Large-Scale Implementation of Precision Medicine in ChinaIn China, the volume of imaging examinations is increasing annually by more than 30%, allowing an increasing number of patients to achieve "early screening, early diagnosis, and early treatment." The imaging enhancement and precision medicine behind diagnostic drugs are emerging and future industries with tremendous potential.From the first-generation X-ray machine to the world's first commercial cyclotron, and from the globe's inaugural full-body MRI system to two Nobel Prize winners who propelled revolutions in medical imaging, GE Healthcare has consistently remained at the technological forefront of the industry. Meanwhile, GE Healthcare has been continuously exploring new industrial chain models in the medical equipment field. Throughout this process, GE Healthcare’s Shanghai base has steadfastly chosen to "deeply cultivate in China."In 1994, GE Healthcare established a contrast agent production base in Pudong, Shanghai.It also became one of the first multinational companies to settle in Pudong's Zhangjiang area.Embarked on a comprehensive path of domestically produced diagnostic drugs, serving the globe.Not far from the Shanghai base, there is another important "position" of GE Healthcare, namelyChina Science Park, and last year established the "Shanghai Innovation Center," which is GE Healthcare's largest innovation entity in Shanghai.Based on the innovation hub model, connecting global resource allocation and scientific innovation capabilities,Currently, it has cooperated with more than 40 partners from all walks of life, and launched more than 30 "+AI" technology integration innovations.GE Healthcare China President and CEO Zhang Yihao stated that the Innovation Center at the China Science Park serves as the "intelligent brain" empowering precision medicine R&D, while the diagnostic pharmaceuticals at the Shanghai site act as the "hands and feet" for implementing precision diagnosis and treatment. Together, they form a synergistic advantage to jointly drive the development of precision medicine. For example, in collaboration with Professor Zhang Wenhong's team from the National Center for Infectious Diseases Medicine, GE Healthcare is advancing early diagnosis and treatment of liver diseases by integrating the strengths of GE Healthcare’s ultrasound, MRI, and diagnostic drugs to create comprehensive precision medicine solutions covering the entire disease course. "As one of the first pharmaceutical plants to settle in the Pudong Zhangjiang Hi-Tech Park, the Shanghai site and the GE Healthcare China Science Park, also located in Pudong Zhangjiang, have achieved leapfrog development from small to large to strong through dual-wheel drive, contributing to the construction of Shanghai's science and technology innovation center and the strategic high ground of the Pudong Zhangjiang Medicine Valley. This enables more medical innovations originating in China to make their way to the world."
GE Healthcare's Three "Innovation Centers" in ChinaWhen localization and domestic production reach a certain scale, the next step of differentiation will definitely lie in innovation. Therefore, while maintaining its strong momentum in domestic production and collaboration, GE Healthcare has upgraded its strategy in China and proposed a new strategic concept of "Boundless Innovation."Based on this, from 2021 to the present three-year period, GE Healthcare has successively launched three "Innovation Centers" in Beijing, Wuxi, and Shanghai. Each center focuses on its own strengths, creating incubation platforms targeting the supply chain, imaging chain, and digital chain respectively.
Beijing "Innovation Center"
Among them, the Beijing "Innovation Center" was established in 2021, relying on GE Healthcare's product design and R&D capabilities in China, as well as the full-scale local production at the Beijing imaging equipment manufacturing base. It focuses on industry-university-research collaborative R&D, advanced manufacturing, lean operations, and other projects in the medical field to accelerate the commercialization of innovative achievements.
In April 2023, Beijing Economic and Technological Development Zone officially awarded GE Healthcare's Beijing Innovation Center as the first technology enterprise incubator in the medical and health sector within the zone — "GE Healthcare Innovation Incubation Platform."The incubator will provide various resource docking services for startup enterprise partners,打通科技成果转化链条, and孵化赋能创新生态.
Wuxi "Innovation Center"
In October 2021, on the occasion of the 25th anniversary of the establishment of GE Healthcare's Wuxi base, GE Healthcare's "Wuxi Innovation Center" was officially launched.The first batch of resident companies, Shen Nan, De Wei, Mai De Intelligent, and Shu Kun Technology, signed strategic cooperation agreements with GE Healthcare.
Wuxi is the second stop of GE Healthcare's "Innovation Center," aiming to effectively integrate the research capabilities of hospitals, experts, universities, and AI companies both in China and abroad, as well as GE Healthcare's full industry chain resources.Focusing on the customized needs of users in China, accelerating the implementation of innovation, and covering functions such as software and hardware development, testing and verification, and product maintenance for ultrasound and patient monitoring devices.
As one of GE Healthcare's largest global R&D centers, the Wuxi base has developed and produced the world's first laptop color ultrasound and the first tablet color ultrasound. It has now become GE Healthcare's largest innovation center for ultrasound products and a production base for medical products such as ventilators, anesthesia machines, and patient monitors.
Shanghai "Innovation Center"
The Shanghai Innovation Center, officially inaugurated in November 2023, represents both the embodiment of GE Healthcare's global precision medicine strategy post-spin-off and another milestone in the deep advancement of its China strategy: "Comprehensive Localization, Boundless Innovation, Win-Win Cooperation."The center is committed to bridging the global resource allocation and scientific innovation capabilities,打通国际国内的产学研用生态链条，to boost the development of Shanghai's science and technology innovation center and the integration of the Yangtze River Delta to new heights.
According to reports,Shanghai "Innovation Center" initially covers an area of 4,000 square meters, with 100 research and development experts. It is the largest and most fully functional innovation entity among the three Innovation Centers of GE Healthcare.Will focus on digital medical technology and application innovation, creating an "intelligent brain" to empower GE Healthcare China R&D, a nurturing carrier for specialized and innovative enterprises, and a one-stop platform to accelerate the transformation of digital medical achievements.
Will continue to empower GE Healthcare's 1,800 R&D engineers in China with digital innovation, serving as the "innovation brain" driving GE Healthcare's R&D in China, while collaborating with ecosystem partners to explore the implementation of cutting-edge digital technologies and integrated diagnostic and treatment solutions.
——
China's medical device market has always attracted major multinational pharmaceutical and device companies to deepen their presence due to its rapidly growing industry scale.
After 30 years of establishment in Shanghai Pudong, the GE Healthcare Shanghai site has become one of GE Healthcare's largest global production bases for medical contrast agents, the largest supplier of contrast agent raw materials in China, and one of the largest manufacturers of non-ionic contrast agents. It has achieved full local production of contrast agents used in CT and MRI enhancement scans in China, and all products have been included in China’s national medical insurance. Today,GE Healthcare Shanghai Base is still"Belt and Road" Excellence in Intelligent Manufacturing Center.Starting from the Shanghai production base for diagnostic pharmaceuticals, GE Healthcare has launched a comprehensive China-based layout in Shanghai, focusing on Pudong, radiating across the Yangtze River Delta region, and covering all of China.GE Healthcare States That Its Confidence in the Chinese Market Will Not Change, and R&D Investment in China Will Double in the Next Three Years, with Innovation Accelerating Twice as Fast.
More exciting content
Welcome to follow WeChat Video Channel
BusinessBusiness cooperation email: qxzj@landianyiliao.com
